News

Carina Schmidt, CEO of Athera, said “We are very excited about the opportunities these agreements present to Athera. They will allow us to reach a large number of

Peregrine Pharmaceuticals, a biopharmaceutical company, has received a new US patent that is expected to strengthen the company’s intellectual property in the field of phospholipid-targeting agents for the

Orcrist Bio, a biotechnology company developing stem cell-mobilizing pharmaceuticals, has received approval from the European Competent Authority in Seville, Spain for its Phase I, open-label, single-ascending-dose, safety study

Millipore, a life science company, and Novozymes Biopharma, a provider of industrial bio-solutions, have launched CellPrime rAlbumin AF-G, a completely animal-free cell culture supplement designed for large scale

CardioDynamics, a developer and manufacturer of noninvasive ICG diagnostic and monitoring devices and ICG sensors, has reported a net loss of $1.46m, or $0.20 per share for the

Cerapedics, a medical device company, has completed a round of private equity financing totaling $15m. NGN Capital led the round and was joined by sole Series A investor

The National Institutes of Health has said it will consider research proposals comparing the cost-effectiveness of biologic medications, cancer treatments and preventive measures for chronic illnesses such as

Genta, a biopharmaceutical company, has completed patient enrollment in Agenda, a Phase III trial of Genasense injection in patients with advanced melanoma. Final accrual totaled 315 subjects. Agenda

PPD, a contract research organization, has acquired Magen BioSciences, a biotechnology company focused on dermatologic therapies based in Waltham, Massachusetts. Under the terms of the deal, PPD purchased